<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585426</url>
  </required_header>
  <id_info>
    <org_study_id>XJYY-LL-FJ-045</org_study_id>
    <nct_id>NCT03585426</nct_id>
  </id_info>
  <brief_title>Vancomycin in the Target Site Treatment of Intracranial Infection</brief_title>
  <official_title>Vancomycin in the Target Site Treatment of Intracranial Infection : a New Strategy for PK/PD Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin, a novel intravenously administered antibiotic, currently plays a key role in the
      management of complicated multi-organism infections. However,current LC-MS/MS methods briefly
      describe parameters and the only reported internal standard was sometimes difficult to
      obtain. In our study,an updated LC-MS/MS method for the quantitative analysis of vancomycin
      in human serum was developed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vancomycin concentration change in serum and cerebrospinal fluid</measure>
    <time_frame>0.5h, 1h, 1.5h, 3h, 5h, 7h, 9h, and 12h after treatment</time_frame>
    <description>Quantitative analysis of vancomycin in serum and cerebrospinal fluid after treatment by an updated LC-MS/MS method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Vancomycin</condition>
  <arm_group>
    <arm_group_label>Vancomycin 1g q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin 1g q8h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.</description>
    <arm_group_label>Vancomycin 1g q12h</arm_group_label>
    <arm_group_label>Vancomycin 1g q8h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In ICU; ventricle drainage was carried out; renal function is normal, namely creatinine
        clearance rate is &gt;60ml/min;

        Exclusion Criteria:

        women in pregnancy or lactation;in patients with renal insufficiency, the creatinine
        clearance rate (Clcr) is less than 60ml/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanyan Jia, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital, the Fourth Military Medical University</affiliation>
  </overall_official>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 1, 2018</last_update_submitted>
  <last_update_submitted_qc>July 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

